{"analyses":[{"ciLowerLimit":"47.3","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"70.4","estimateComment":"Percent","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","pValue":"<.0001","paramType":"Response rate","paramValue":"59","statisticalMethod":"percent"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"}],"units":"Participants"}],"description":"The intracranial response rate is defined as the percentage of subjects achieving a confirmed intracranial CR or PR. This is based on investigator-assessed best intracranial response.","groups":[{"description":"Subjects will receive dabrafenib 150 milligram (mg) twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity.","id":"OG000","title":"Cohort A"}],"paramType":"NUMBER","populationDescription":"All Treated population - All subjects who receive at least one dose of study medication are comprised the All Treated subjects (ATS) population.","reportingStatus":"POSTED","timeFrame":"From the start of treatment until disease progression or the start of new anti-cancer therapy","title":"Intracranial Response (IR) Rate in Cohort A","type":"PRIMARY","unitOfMeasure":"Number of participants"}